research The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
Search
for
Sort by
Research
210-240 / 1000+ results research Role of janus kinase inhibitors in the treatment of alopecia areata
Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
research Novel TMEM173 Mutation and the Role of Disease Modifying Alleles
A new mutation in the STING protein causes a range of symptoms and its severity may be affected by other genetic variations; treatment with a specific inhibitor showed improvement in one patient.
research New and Emerging Therapies for Alopecia Areata
Emerging therapies like JAK inhibitors show promise for hair regrowth in alopecia areata.
research An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
research A novel therapeutic paradigm for patients with extensive alopecia areata
New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
research JAK inhibition in the treatment of alopecia areata – a promising new dawn?
JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
research New drugs under investigation for the treatment of alopecias
New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
research Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis
Baricitinib is the most effective treatment for alopecia areata.
research The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature
JAK inhibitors show promise for treating hair loss in alopecia areata but need more clinical trials to confirm safety and effectiveness.
research Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature
JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.
research Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
Baricitinib might help treat hair loss in lupus patients, but more research is needed.
research Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
research Predictors and Management of Inadequate Response to JAK Inhibitors in Alopecia Areata
Switching JAK inhibitors or using dupilumab may help some alopecia areata patients who don't respond well to initial treatments.
research Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
research Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature
Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
research Janus kinase inhibitors for alopecia areata
JAK inhibitors offer new hope for treating severe alopecia areata.
research Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
research Emerging drugs for the treatment of alopecia areata
New drugs for alopecia areata show promise but aren't universally effective, and hair loss often returns after stopping treatment.
research Shedding light on therapeutics in alopecia and their relevance to COVID-19
Some alopecia treatments might help treat COVID-19, but more research is needed.
research Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
research Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.
research Janus Kinase Inhibitors against Other Biological Treatments in Alopecia Areata
Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
research Immune therapies for alopecia areata: evidence and new perspectives
New treatments for alopecia areata focus on targeting immune responses for better results.
research II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata
Treat alopecia areata with personalized plans, using corticosteroids for mild cases and Janus Kinase inhibitors for severe cases, while also offering psychological support.
research A review of Janus kinase inhibitor use in scarring alopecia
Janus kinase inhibitors are promising for treating scarring alopecia, but more research is needed for safety and personalized treatments.
research European expert consensus statement on the systemic treatment of alopecia areata
Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
research Inhibition of T-cell activity in alopecia areata: recent developments and new directions
New treatments targeting T-cell pathways are needed for better alopecia areata management.
research [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
research The Latest Trends of Treatment for Alopecia
Finasteride, Dutasteride, and Minoxidil are effective for hair growth, while new treatments like laser therapy and PRP show promise with few side effects.